10:01 AM EST - NovaBay Pharma Inc. : said the United States Patent and Trademark Office has approved the issuance of U.S. Patent to the company for novel Aganocide compounds including NVC-422. The patent will expire on April 24, 2026. The company has filed additional patent applications including ones for compositions of matter of additional Aganocide compounds, methods of use and formulations, and is preparing further applications in other areas. NovaBay Pharma Inc.
shares T.NBY are trading unchanged at $1.15.
